Get the Stockscreener App
0.65
28.57%
-0.26
Pre-market:
.67
0.02
+3.08%
Clearmind Medicine Inc stock is traded at $0.65, with a volume of 2.16M.
It is down -28.57% in the last 24 hours and down -16.67% over the past month.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.
See More
Previous Close:
$0.91
Open:
$0.8
24h Volume:
2.16M
Relative Volume:
3.58
Market Cap:
$1.56M
Revenue:
-
Net Income/Loss:
$-8.44M
P/E Ratio:
-4.1747
EPS:
-0.1557
Net Cash Flow:
$-4.41M
1W Performance:
-50.38%
1M Performance:
-16.67%
6M Performance:
-98.28%
1Y Performance:
-98.23%
1-Day Range:
$0.6454
$0.80
1-Week Range:
$0.6454
$1.49
52-Week Range:
$0.5949
$52.40
Clearmind Medicine Inc Stock (CMND) Company Profile
Compare CMND vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMND
Clearmind Medicine Inc
|
0.65 | 2.18M | 0 | -8.44M | -4.41M | -0.1557 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 112.35B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.71B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 52.29B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 44.48B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 35.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Clearmind Medicine Inc Stock (CMND) Latest News
Clearmind shares surge as CMND-100 achieves primary endpoint in clinical trial - MSN
Clearmind gets safety board nod to continue alcohol disorder trial - Investing.com
Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial - The Manila Times
Alcohol disorder drug advances after no serious adverse events - Stock Titan
Clearmind Medicine (CMND) raises $1.58M cash via $1.75M notes - Stock Titan
12 Health Care Stocks Moving In Tuesday's Intraday SessionAdagio Medical Holdings (NASDAQ:ADGM), Allog - Benzinga
Crude Oil Falls Sharply; Wells Fargo Earnings Miss ViewsAvanos Medical (NYSE:AVNS), Clearmind Medicine - Benzinga
Clearmind (Nasdaq: CMND) CMND-100 meets key safety goal in AUD trial - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Clearmind’s CMND-100 meets primary endpoint in phase I/IIa trial - Investing.com India
Clearmind Medicine's CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder - Bitget
Clearmind Medicine Inc. Reports Positive Phase I/IIa Trial Results for CMND-100 in Treating Alcohol Use Disorder - Quiver Quantitative
Clearmind Medicine stock surges on phase trial results By Investing.com - Investing.com Australia
Clearmind Medicine’s CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder - The Manila Times
Clearmind Medicine stock surges on phase trial results - Investing.com
Alcohol use disorder drug clears early safety test at higher dose - Stock Titan
CMND Stock Price, Quote & Chart | CLEARMIND MEDICINE INC (NASDAQ:CMND) - ChartMill
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
CMND Forecast, Price Target & Analyst Ratings | CLEARMIND MEDICINE INC (NASDAQ:CMND) - ChartMill
CMND PE Ratio & Valuation, Is CMND Overvalued - Intellectia AI
CMND Technical Analysis & Stock Price Forecast - Intellectia AI
Clearmind gets safety board approval to continue AUD trial - Investing.com
Psychedelic: Clearmind completes treatment, follow-up for CMND-100 trial - TipRanks
Bull Bear: What analysts say about Clearmind Medicine Inc stockWeekly Trading Summary & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Clearmind completes treatment for 18 participants in AUD trial By Investing.com - Investing.com South Africa
[EFFECT] Clearmind Medicine Inc. SEC Filing - Stock Titan
Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders - MarketScreener
Clearmind completes treatment for 18 participants in AUD trial - Investing.com
Clearmind Medicine Announces Successful Completion Of Treatment Of Cmnd-100 For Alcohol Use Disorder - TradingView — Track All Markets
Clearmind Medicine (Nasdaq: CMND) completes treatment for 18 CMND-100 patients - Stock Titan
Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder - bitget.com
Clearmind says its alcohol disorder drug trial cleared 18 patients - Stock Titan
Oruka Therapeutics and Clearmind Medicine Vie for Investor Dollars - National Today
Clearmind files patent application in India for psychedelic compounds By Investing.com - Investing.com South Africa
Clearmind files patent application in India for psychedelic compounds - in.investing.com
Clearmind Medicine Files Patent Application In India For Next-Gen Psychedelic Compounds To Treat Mental Health Disorders - TradingView
Clearmind Medicine Inc. Files Patent Application in India for Next-Generation Psychedelic Compounds Targeting Mental Health and Addiction - Quiver Quantitative
[6-K] Clearmind Medicine Inc. Current Report (Foreign Issuer) | CMND SEC FilingForm 6-K - Stock Titan
Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to ... - Caledonian Record
Market Overview: Is Clearmind Medicine Inc in a bullish channel2026 Big Picture & Real-Time Buy Signal Alerts - baoquankhu1.vn
[POS AM] Clearmind Medicine Inc. SEC Filing - Stock Titan
CMND SEC FilingsClearmind Medici 10-K, 10-Q, 8-K Forms - Stock Titan
CMND Technical Analysis | Trend, Signals & Chart Patterns | CLEARMIND MEDICINE INC (NASDAQ:CMND) - ChartMill
Analyst Upgrade: Is Clearmind Medicine Inc a turnaround story2026 Catalysts & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Form 6K Clearmind Medicine Inc For: 19 March - Investing.com
[6-K] Clearmind Medicine Inc. Cur... | CMND SEC FilingForm 6-K - Stock Titan
Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder - manilatimes.net
Clearmind Medicine Inc. Advances CMND-100 Clinical Trial for Alcohol Use Disorder with Successful Cohort Treatment - Quiver Quantitative
Clearmind Medicine regains compliance with NASDAQ minimum bid price rule - MSN
Clearmind Medicine secures six patents in Hong Kong By Investing.com - Investing.com South Africa
Clearmind Medicine Inc Stock (CMND) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):